Benzinga

Benzinga

Benzinga

samedi, août 22

Werewolf Therapeutics Inc

HOWLNASDAQ
Trade with Public
Trade with Public
$0.8735
0.44102.57%
À la clôture: Aug 21, 5:00 PM EST
$0.8256
-0.0479-5.48%
Après les heures: 7:59 PM EST
PRO
Pourquoi cela bouge-t-il ?:Werewolf Therapeutics shares are trading higher after the company announced...
Fusions et acquisitions: Ambros Therapeutics, Inc announced today it will be merged with Werewolf Therapeutics (HOWL) for $47.5M paid in stock
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Werewolf Therapeutics Financials

Werewolf Therapeutics (HOWL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.29) by 127.59 percent. This is a 120 percent increase over losses of $(0.40) per share
Benzinga Newsdesk

PRO
Werewolf Therapeutics Q1 EPS $(0.28), Inline

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 30 percent increase over losses of $(0.40) per share from the same period last year.
Benzinga Newsdesk

Earnings Scheduled For March 27, 2026

Benzinga Insights

PRO
Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.35) by 43.18 percent. This is a 56.52 percent increase over losses of $(0.46) per share
Benzinga Newsdesk

PRO
Werewolf Therapeutics Q3 EPS $(0.36) Beats $(0.39) Estimate

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 5.26 percent increase over losses of $(0.38) per share
Benzinga Newsdesk

PRO
Werewolf Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.36 percent. This is a 6.98 percent increase over losses of $(0.43) per share
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved